Extracellular GRP78 inhibitors for the removal of treatment resistant cancers
GRP78 antagonists like CBT300 address treatment-resistant cancers by inhibiting extracellular GRP78, reversing chemoresistance and immune suppression, and inhibiting cancer stem cells, thereby enhancing chemotherapy efficacy and improving survival rates in drug-resistant cancers.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- CREATIVE BIOTHERAPEUTICS LLC
- Filing Date
- 2024-11-18
- Publication Date
- 2026-06-18
AI Technical Summary
Existing cancer treatments, including chemotherapy, face significant challenges due to chemoresistance and immune suppression, leading to treatment-resistant cancers that are often incurable and result in high mortality rates, particularly in aggressive forms like metastatic breast cancer and glioblastoma.
The use of GRP78 antagonists, such as CBT300, which target and inhibit the extracellular form of Glucose-Regulated Protein 78 (GRP78) on tumor cells, disrupting signaling pathways that induce drug resistance, immune suppression, and cancer stem cell formation, thereby enhancing the effectiveness of chemotherapy and immunotherapy.
GRP78 antagonists like CBT300 demonstrate the potential to reverse chemoresistance, reduce immune suppression, and inhibit cancer stem cells, leading to significant tumor regression and improved survival rates in drug-resistant cancers by synergizing with lower doses of chemotherapy.